Link:
Correction: GUERBET : Financial agenda for 2025
Related Post
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - February 2nd, 2025
- Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - February 2nd, 2025
- Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - February 2nd, 2025
- 23andMe Launches New Genetic Report on Osteoporosis - February 2nd, 2025
- Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older - February 2nd, 2025
- CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference - February 2nd, 2025
- Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - February 2nd, 2025
- Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - February 2nd, 2025
- Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - February 2nd, 2025
- NewGen Announces Reverse Stock Split - February 2nd, 2025
- Immutep Quarterly Activities Report Q2 FY25 - February 2nd, 2025
- Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - February 2nd, 2025
- Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade - February 2nd, 2025
- Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - February 2nd, 2025
- Bavarian Nordic – Completion of Share Buy-Back Program - February 2nd, 2025
- Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU - February 2nd, 2025
- Annovis Bio, Inc. Announces Proposed Public Offering - February 2nd, 2025
- Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of... - January 31st, 2025
- PacBio Announces Appointment of Chris Smith to Board of Directors - January 31st, 2025
- SPR Announces Presentation of Four Abstracts Featuring the SPRINT® PNS System at NANS 2025 - January 31st, 2025
- Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
- PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
- Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
- Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
- Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
- Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
- Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
- Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
- Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
- Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
- Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
- Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
- BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
- Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
- Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
- Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
- Alumis Strengthens Leadership Team with Key Appointments - January 28th, 2025
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - January 28th, 2025
- 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - January 28th, 2025
- March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma - January 28th, 2025
- Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - January 28th, 2025
- Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement - January 28th, 2025
- Better Choice Company Signs Non-Binding Term Sheet to Sell Halo Asia for $6.5 Million in Cash at Closing and a 5-Year Royalty Valued at a Minimum of... - January 28th, 2025
- BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs - January 28th, 2025
- Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study - January 28th, 2025
- Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions - January 28th, 2025
- Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology - January 28th, 2025
- Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares - January 28th, 2025
- Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding - January 28th, 2025
- Spectral AI Completes Pediatric Enrollment in Emergency Departments for U.S. Burn Pivotal Study - January 28th, 2025
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update - January 28th, 2025
- Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development - January 28th, 2025
- Eyenovia Announces 1-for-80 Reverse Stock Split - January 28th, 2025
- ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference - January 28th, 2025
- 23andMe Reports Third Quarter Fiscal Year 2025 Financial Results - January 28th, 2025
- 23andMe Special Committee Announces Exploration of Strategic Alternatives - January 28th, 2025
- Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of... - January 25th, 2025
- PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider - January 25th, 2025
- America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search - January 25th, 2025
- LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) - January 25th, 2025
- Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 - January 25th, 2025
- Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual... - January 25th, 2025
- Vincerx Pharma, Inc. Announces Reverse Stock Split - January 25th, 2025
- Impact BioMedical Inc. to Present at The Microcap Conference - January 25th, 2025
- Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - January 25th, 2025
- Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference - January 25th, 2025
- Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity - January 25th, 2025
- X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - January 25th, 2025
- Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - January 25th, 2025
- Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care - January 25th, 2025
- Gelteq Appoints Matthew Jones as Head of Sports Performance - January 25th, 2025
- Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia - January 25th, 2025
- AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET - January 25th, 2025
- Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in... - January 25th, 2025
- Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated... - January 25th, 2025
- Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure - January 25th, 2025
- Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - January 23rd, 2025
- Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement - January 23rd, 2025
- Spectral AI Provides Update to Investors - January 23rd, 2025
Recent Comments